SLC5A2 and chronic kidney disease: SGLT-2 inhibitors were associated with a lower incidence of cardiovascular death or hospitalization for heart failure among patients with CKD, compared with placebo: RR 0.79 (95% CI 0.74–0.84; P < 0.001) (Supplemental Fig. 4 and Table 3).